The Ugi4CR as effective tool to access promising anticancer isatin-based α-acetamide carboxamide oxindole hybrids

dc.contributor.authorMarques, Carolina S.
dc.contributor.authorGonzález-Bakker, Aday
dc.contributor.authorPadrón, José M.
dc.date.accessioned2025-06-13T12:21:05Z
dc.date.available2025-06-13T12:21:05Z
dc.date.issued2024
dc.description.abstractConsidering early-stage drug discovery programs, the Ugi four-component reaction is a valuable, flexible, and pivotal tool, facili- tating the creation of two new amide bonds in a one-pot fashion to effectively yield the desired α-aminoacylamides. Here, we high- light the reputation of this reaction approach to access number and scaffold diversity of a library of isatin-based α-acetamide carboxamide oxindole hybrids, promising anticancer agents, in a mild and fast sustainable reaction process. The library was tested against six human solid tumor cell lines, among them, non-small cell lung carcinoma, cervical adenocarcinoma, breast cancer and colon adenocarcinoma. The most potent compounds 8d, 8h and 8k showed GI50 values in the range of 1–10 μM.por
dc.identifier.authoremailcarolsmarq@uevora.pt
dc.identifier.authoremailnd
dc.identifier.authoremailnd
dc.identifier.doi10.3762/bjoc.20.104por
dc.identifier.scientificarea307por
dc.identifier.urihttps://doi.org/10.3762/bjoc.20.104
dc.identifier.urihttp://hdl.handle.net/10174/38587
dc.language.isoengpor
dc.peerreviewednopor
dc.publisherBeilstein-Institut Zur Forderung der Chemischen Wissenschaftenpor
dc.rightsopenAccesspor
dc.subjectcancerpor
dc.subjectUgi4CRpor
dc.subjectGI50por
dc.subjectisatinpor
dc.subjectoxindolepor
dc.titleThe Ugi4CR as effective tool to access promising anticancer isatin-based α-acetamide carboxamide oxindole hybridspor
dc.typearticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Beilstein JOC 2024.pdf
Size:
1.69 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
3.89 KB
Format:
Item-specific license agreed upon to submission
Description: